Clinical Trial Search

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: To Determine if the LigaSure Device, Which we Routinely Used for Removal of Tubes and Ovaries, is Effective at Destroying All Tubal Cells Comprising the Fallopian Tube…

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Progression-free Survival at 6 Months — 6.5 percentage of participants

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement — .143; .959 Proportion of Cytuity Cell Samples

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: PFS — 29.8 Months

Primary: Number of Participants With Treatment Success — 23 Participants

Primary: Overall Objective Response — 10; 13; 11; 4 participants

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Dose Limiting Toxicity (DLT) — 2; 3; 4 Dose Limiting Toxicities

Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 0 Participants

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in…

Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants

Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg

Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants

Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…

Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0; 0 Participants

Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341

Primary: Objective Tumor Response — 4; 8; 8; 32 Participants